Medical - Healthcare Plans
Compare Stocks
2 / 10Stock Comparison
OSCR vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
OSCR vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Healthcare Plans | Biotechnology |
| Market Cap | $5.41B | $1712.35T |
| Revenue (TTM) | $13.30B | $0.00 |
| Net Income (TTM) | $-39M | $-168M |
| Gross Margin | 17.4% | — |
| Operating Margin | 0.1% | — |
| Forward P/E | 34.7x | — |
| Total Debt | $430M | $22M |
| Cash & Equiv. | $2.77B | $194M |
OSCR vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Oscar Health, Inc. (OSCR) | 100 | 77.6 | -22.4% |
| DBV Technologies S.… (DBVT) | 100 | 37.5 | -62.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OSCR vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
OSCR is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 27.5%, EPS growth -18.7%, 3Y rev CAGR 41.6%
- -40.0% 10Y total return vs DBVT's -87.0%
- 27.5% revenue growth vs DBVT's -100.0%
DBVT carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 1.26
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.5% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 0.3% margin vs OSCR's -0.3% | |
| Stability / Safety | Beta 1.26 vs OSCR's 1.84, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +110.4% vs OSCR's +22.6% | |
| Efficiency (ROA) | -0.6% ROA vs DBVT's -89.0% |
OSCR vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
OSCR leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
OSCR and DBVT operate at a comparable scale, with $13.3B and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $13.3B | $0 |
| EBITDAEarnings before interest/tax | $40M | -$112M |
| Net IncomeAfter-tax profit | -$39M | -$168M |
| Free Cash FlowCash after capex | $2.8B | -$151M |
| Gross MarginGross profit ÷ Revenue | +17.4% | — |
| Operating MarginEBIT ÷ Revenue | +0.1% | — |
| Net MarginNet income ÷ Revenue | -0.3% | — |
| FCF MarginFCF ÷ Revenue | +21.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +52.6% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +125.0% | +91.5% |
Valuation Metrics
Evenly matched — OSCR and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $5.4B | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $3.1B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -12.35x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 34.65x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.46x | — |
| Price / BookPrice ÷ Book value/share | 5.58x | 0.66x |
| Price / FCFMarket cap ÷ FCF | 5.11x | — |
Profitability & Efficiency
OSCR leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
OSCR delivers a -3.3% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to OSCR's 0.44x.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -3.3% | -130.2% |
| ROA (TTM)Return on assets | -0.6% | -89.0% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -25.3% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.44x | 0.13x |
| Net DebtTotal debt minus cash | -$2.3B | -$172M |
| Cash & Equiv.Liquid assets | $2.8B | $194M |
| Total DebtShort + long-term debt | $430M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -0.57x | -189.82x |
Total Returns (Dividends Reinvested)
OSCR leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OSCR five years ago would be worth $9,271 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs OSCR's +22.6%. The 3-year compound annual growth rate (CAGR) favors OSCR at 40.5% vs DBVT's 6.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +39.4% | +4.9% |
| 1-Year ReturnPast 12 months | +22.6% | +110.4% |
| 3-Year ReturnCumulative with dividends | +177.5% | +19.7% |
| 5-Year ReturnCumulative with dividends | -7.3% | -69.1% |
| 10-Year ReturnCumulative with dividends | -40.0% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +40.5% | +6.2% |
Risk & Volatility
Evenly matched — OSCR and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than OSCR's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OSCR currently trades 87.7% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.84x | 1.26x |
| 52-Week HighHighest price in past year | $23.80 | $26.18 |
| 52-Week LowLowest price in past year | $10.69 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +87.7% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 78.5 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 6.5M | 252K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates OSCR as "Hold" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs -19.7% for OSCR (target: $17).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $16.75 | $46.33 |
| # AnalystsCovering analysts | 11 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
OSCR leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
OSCR vs DBVT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is OSCR or DBVT a better buy right now?
Analysts rate DBV Technologies S.
A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OSCR or DBVT?
Over the past 5 years, Oscar Health, Inc.
(OSCR) delivered a total return of -7. 3%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: OSCR returned -40. 0% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OSCR or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Oscar Health, Inc. 's 1. 84β — meaning OSCR is approximately 46% more volatile than DBVT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 44% for Oscar Health, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — OSCR or DBVT?
On earnings-per-share growth, the picture is similar: DBV Technologies S.
A. grew EPS -347. 5% year-over-year, compared to -1865. 9% for Oscar Health, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — OSCR or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -3. 8% for Oscar Health, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -3. 4% for OSCR. At the gross margin level — before operating expenses — OSCR leads at 14. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is OSCR or DBVT more undervalued right now?
Analyst consensus price targets imply the most upside for DBVT: 131.
8% to $46. 33.
07Which pays a better dividend — OSCR or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is OSCR or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Oscar Health, Inc. (OSCR) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -87. 0%, OSCR: -40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between OSCR and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: OSCR is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.